The abstract is read at the publisher; the summary is JClub's.
Baseline and response reporting in myelodysplastic syndromes/neoplasms trials shows substantial variability, with baseline ANC reported in 16% of lower-risk and 23% of higher-risk studies.
- Why it matters: Inconsistent trial element reporting can limit accurate interpretation and cross-trial comparison, especially for patient characteristics and response criteria in MDS.
- What they did: The International Consortium for MDS systematically reviewed peer-reviewed full-text therapeutic trial manuscripts published from January 1, 2015 to December 31, 2024, assessing predefined reporting elements and then used a modified-Delphi process to draft consensus recommendations.
- The result: The analysis found nonstandard response endpoints, including six RBC transfusion independence definitions in lower-risk trials and seven overall response rate definitions in higher-risk trials, enabling benchmark templates for clearer MDS trial reporting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.